Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs BIO-TECHNE Corp — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.62, while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | TECH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $72.12 |
52-Week Low | $12.03 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.41, up 0.4% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The fund generates weekly dividends, with recent payouts ranging from $0.10 to $0.21 per share. News coverage highlights the trade-off between income and potential upside capture relative to NVIDIA's stock performance.
The outlook hinges on investor preference for consistent income versus capital appreciation. Risks include underperformance versus NVIDIA during strong rallies and fee drag. Sentiment is mixed, with some questioning the strategy's long-term value amid NVIDIA's volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
